Anagrelide: Finding new use as an adjuvant therapy in cancer management

Dr Richard Franklin, Anagrelide Project Director at SUDA Pharmaceuticals Ltd, is pioneering a radically new application which would see the platelet-lowering drug anagrelide developed as an oromucosal spray formulation. This has the potential to make the most of its recently discovered ability to block cancer cell-stimulated platelet formation and to inhibit cancer cell migration towards platelet precursors (megakaryocytes) while at […]

Read More…